Logo image of IART

INTEGRA LIFESCIENCES HOLDING (IART) Stock Price, Quote, News and Overview

NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD

26.05  +0.45 (+1.76%)

After market: 26.05 0 (0%)

IART Quote, Performance and Key Statistics

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (1/24/2025, 8:00:02 PM)

After market: 26.05 0 (0%)

26.05

+0.45 (+1.76%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High45.42
52 Week Low16.81
Market Cap2.01B
Shares77.16M
Float74.67M
Yearly Dividend0
Dividend YieldN/A
PE10.5
Fwd PE10.16
Earnings (Next)02-19 2025-02-19/amc
IPO08-16 1995-08-16


IART short term performance overview.The bars show the price performance of IART in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

IART long term performance overview.The bars show the price performance of IART in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of IART is 26.05 USD. In the past month the price increased by 18.36%. In the past year, price decreased by -37.74%.

INTEGRA LIFESCIENCES HOLDING / IART Daily stock chart

IART Latest News, Press Releases and Analysis

News Image
13 days ago - Integra LifeSciences Holdings Corporation

Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)

New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge...

News Image
2 months ago - Integra LifeSciences Holdings Corporation

Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research

The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior...

News Image
3 months ago - Benzinga

Why Is Integra LifeSciences Stock Soaring On Monday?

Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.

News Image
3 months ago - Integra LifeSciences Holdings Corporation

Integra LifeSciences Reports Third Quarter 2024 Financial Results

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...

IART Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.77 216.86B
ISRG INTUITIVE SURGICAL INC 79.68 208.03B
SYK STRYKER CORP 33.88 150.32B
BSX BOSTON SCIENTIFIC CORP 43.19 150.24B
MDT MEDTRONIC PLC 17.18 115.65B
BDX BECTON DICKINSON AND CO 18.5 70.60B
EW EDWARDS LIFESCIENCES CORP 25.84 40.69B
GEHC GE HEALTHCARE TECHNOLOGY 21.01 40.51B
RMD RESMED INC 30.22 36.77B
IDXX IDEXX LABORATORIES INC 39.76 35.64B
DXCM DEXCOM INC 52.21 34.67B
PHG KONINKLIJKE PHILIPS NVR- NY 19.9 25.26B

About IART

Company Profile

IART logo image Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 3,946 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The firm provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Company Info

INTEGRA LIFESCIENCES HOLDING

1100 Campus Road

Princeton NEW JERSEY 08540 US

CEO: Peter J. Arduini

Employees: 3946

Company Website: https://www.integralife.com/

Investor Relations: https://investor.integralife.com/

Phone: 16092750500

IART FAQ

What is the stock price of IART?

The current stock price of IART is 26.05 USD.


What is the symbol for INTEGRA LIFESCIENCES HOLDING stock?

The exchange symbol of INTEGRA LIFESCIENCES HOLDING is IART and it is listed on the Nasdaq exchange.


On which exchange is IART stock listed?

IART stock is listed on the Nasdaq exchange.


Is IART a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IART, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IART.


Does IART stock pay dividends?

IART does not pay a dividend.


When does IART stock report earnings?

IART will report earnings on 2025-02-19, after the market close.


What is the Price/Earnings (PE) ratio of IART?

The PE ratio for IART is 10.5. This is based on the reported non-GAAP earnings per share of 2.48 and the current share price of 26.05 USD.


What is the Short Interest ratio of IART stock?

The outstanding short interest for IART is 4.34% of its float.


IART Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to IART. When comparing the yearly performance of all stocks, IART is a bad performer in the overall market: 60.38% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IART Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to IART. While IART is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IART Financial Highlights

Over the last trailing twelve months IART reported a non-GAAP Earnings per Share(EPS) of 2.48. The EPS increased by -21.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -0.16%
ROE -0.43%
Debt/Equity 0.79
Chartmill High Growth Momentum
EPS Q2Q%-46.05%
Sales Q2Q%-0.93%
EPS 1Y (TTM)-21.27%
Revenue 1Y (TTM)1.45%

IART Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 52% to IART. The Buy consensus is the average rating of analysts ratings from 18 analysts.

For the next year, analysts expect an EPS growth of -19.35% and a revenue growth 4.44% for IART


Ownership
Inst Owners95.17%
Ins Owners3.12%
Short Float %4.34%
Short Ratio4.06
Analysts
Analysts52.22
Price Target26.52 (1.8%)
EPS Next Y-19.35%
Revenue Next Year4.44%